These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 11868865)

  • 1. Present status of various inotropic agents in heart failure.
    Mittal SR; Maheshwari N
    J Assoc Physicians India; 2001 Nov; 49():1095-9. PubMed ID: 11868865
    [No Abstract]   [Full Text] [Related]  

  • 2. Rationale and design of the enoximone clinical trials program.
    Lowes BD; Shakar SF; Metra M; Feldman AM; Eichhorn E; Freytag JW; Gerber MJ; Liard JF; Hartman C; Gorczynski R; Evans G; Linseman JV; Stewart J; Robertson AD; Roecker EB; Demets DL; Bristow MR
    J Card Fail; 2005 Dec; 11(9):659-69. PubMed ID: 16360960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current role of non-digitalis inotropic agents in acute and chronic treatment of heart failure].
    Dei Cas L; Nodari S; Raddino R; Metra M; Pelà G; Nardi M
    Cardiologia; 1994 Mar; 39(3):209-15. PubMed ID: 8039201
    [No Abstract]   [Full Text] [Related]  

  • 4. [Inotropic agents in advanced and refractory heart failure].
    Mangiavacchi M; Gronda E
    Ital Heart J Suppl; 2003 Jan; 4(1):3-7. PubMed ID: 12690928
    [No Abstract]   [Full Text] [Related]  

  • 5. [Positive inotropic agents in heart failure. Clinico-pharmacological evidence for medical practice].
    Rohde LE; Ribeiro JP
    Arq Bras Cardiol; 1994 Dec; 63(6):537-42. PubMed ID: 7605243
    [No Abstract]   [Full Text] [Related]  

  • 6. Intermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failure.
    Drakos SG; Kanakakis JV; Nanas S; Bonios M; Kaldara E; Katsaros F; Pantsios C; Nanas JN
    J Cardiovasc Pharmacol; 2009 Feb; 53(2):157-61. PubMed ID: 19188832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of clinical outcome in advanced heart failure patients on continuous intravenous milrinone therapy.
    Bhat G
    ASAIO J; 2006; 52(6):677-81. PubMed ID: 17117058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Use of inotropic agents in the treatment of cardiac insufficiency].
    Coma Canella I; López-Sendón J
    Rev Esp Cardiol; 1984; 37(3):186-95. PubMed ID: 6150525
    [No Abstract]   [Full Text] [Related]  

  • 9. [Efficacy and problems of cardiotonic agents viewed from physiopathology of chronic congestive heart failure].
    Asanoi H; Inoue H
    Nihon Naika Gakkai Zasshi; 1995 Sep; 84(9):1465-9. PubMed ID: 8537751
    [No Abstract]   [Full Text] [Related]  

  • 10. [Positive inotropic therapy of cardiac failure: old and new drugs, controversies and tests].
    Sfrisi C; Cocco G
    Clin Ter; 1984 Oct; 111(2):159-67. PubMed ID: 6239739
    [No Abstract]   [Full Text] [Related]  

  • 11. An overview of inotropic agents.
    Vroom MB
    Semin Cardiothorac Vasc Anesth; 2006 Sep; 10(3):246-52. PubMed ID: 16959760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure).
    Stevenson LW; Miller LW; Desvigne-Nickens P; Ascheim DD; Parides MK; Renlund DG; Oren RM; Krueger SK; Costanzo MR; Wann LS; Levitan RG; Mancini D;
    Circulation; 2004 Aug; 110(8):975-81. PubMed ID: 15313942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognosis assessment in patients with decompensated heart failure. Simple clinical parameters or neurohormonal factors.
    Aronson D; Burger AJ
    Ital Heart J; 2004 Jul; 5(7):494-7. PubMed ID: 15487265
    [No Abstract]   [Full Text] [Related]  

  • 14. [Is heart rate reduction beneficial to patients with heart insufficiency? Focus on beta-blockade].
    Henriksen OM; Gadsbøll N
    Ugeskr Laeger; 2002 Jan; 164(5):615-9. PubMed ID: 11871210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ambulatory vasodilator therapy in heart failure: systematic review of the literature and personal observational experience.
    Pacher R; Stanek B
    Eur J Heart Fail; 1999 Aug; 1(3):263-8. PubMed ID: 10935673
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical use of inotropic therapy for heart failure: looking backward or forward? Part II: chronic inotropic therapy.
    Stevenson LW
    Circulation; 2003 Jul; 108(4):492-7. PubMed ID: 12885733
    [No Abstract]   [Full Text] [Related]  

  • 17. Between Scylla and Charybdis: The choice of inotropic agent for decompensated heart failure.
    Felker GM; O'connor CM
    Am Heart J; 2001 Dec; 142(6):932-3. PubMed ID: 11717593
    [No Abstract]   [Full Text] [Related]  

  • 18. Severe heart failure: balancing length and quality of life.
    Harv Heart Lett; 1999 Jun; 9(10):1-2. PubMed ID: 10233785
    [No Abstract]   [Full Text] [Related]  

  • 19. [Study of heart failure. Is phytotherapy effective?].
    MMW Fortschr Med; 2001 Jun; 143(25):59. PubMed ID: 11469004
    [No Abstract]   [Full Text] [Related]  

  • 20. Do positive inotropic agents adversely affect the survival of patients with chronic congestive heart failure? I. Introduction.
    Cody RJ
    J Am Coll Cardiol; 1988 Aug; 12(2):559-61. PubMed ID: 3392348
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.